Market Cap
$4.8B
HAE
HAEMONETICS CORP
$104.84 ▲ +0.45%
Prev close $104.37Market cap$4.8B
ConsensusBuy
12-mo target$111.50 (+6.4%)
▲ Bullish
Analyst conviction 7/10
27 New Institutional Positions23 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on HAE right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (73%)
Inst. Holders
50 funds
Inst. Value
$3.1B
Inst. Activity
27 buys / 23 sells
SEC Reports
5
Price chart 30d +1.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 earnings
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Compan
Sep 30, 2026 Event
Aug 18, 2026 SEC Haemonetics Corporation v. Terumo BCT, Inc.
Court ruling (cod) — Docket: 1:25-cv-01409
Haemonetics entered into a non-exclusive supply agreement with CSL Plasma for use of its NexSys PCS devices and disposab
8-K — Impact 3/10
Jul 24, 2026 Insider
Pomeroy Claire was granted 2,538 shares
Director
Jul 24, 2026 Insider
KROLL MARK W was granted 2,538 shares
Director
Jul 24, 2026 Insider
Johnson Lloyd Emerson was granted 2,538 shares
Director
Jun 30, 2026 Inst.
ARIEL INVESTMENTS, LLC — NEW
2,060,966 shares ($154.6M)
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
1,510,120 shares ($113.3M)
Analyst ratings buy % +9.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
73% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 17, 2026 | Citigroup | UPGRADE | Buy | 55% |
| Sep 3, 2026 | Raymond James | MAINTAIN | Outperform | 54% |
| Aug 21, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Aug 19, 2026 | Barrington Research | MAINTAIN | Outperform | 55% |
| Aug 18, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Aug 7, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Aug 7, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Aug 6, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Jul 15, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jun 26, 2026 | BTIG | REITERATE | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 6 | 4 | 0 | 0 | 73% | |
| Aug 1, 2026 | 5 | 6 | 4 | 0 | 0 | 73% | |
| Jul 1, 2026 | 5 | 6 | 4 | 0 | 0 | 73% | |
| Jun 1, 2026 | 5 | 6 | 4 | 0 | 0 | 73% | |
| May 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Apr 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Mar 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Feb 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% |
Price targets
Where 10 covering analysts think HAE trades over the next 12 months.
$111.50 +6.4% upside Buy
Current$104.84 Low$86.00 Median$116.50 High$125.00 10 analysts
$86.00$125.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 5 neutral · avg impact 3.2/10.
NEUTRAL8-K3/10
Haemonetics entered into a non-exclusive supply agreement with CSL Plasma for use of its NexSys PCS
Aug 18, 2026
NEUTRALDEFA14A5/10
Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, f
Jun 9, 2026
NEUTRAL8-K2/10
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood C
Jun 5, 2026
NEUTRAL8-K4/10
Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.
May 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
earnings
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 20
Sep 30, 2026
Enforcement
Haemonetics Corporation v. Terumo BCT, Inc.
Court ruling (cod) — Docket: 1:25-cv-01409
Aug 6, 2026
earnings
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced t
Aug 6, 2026
earnings_calendar
HAE Q1 2027 Earnings Scheduled — 2026-08-06
Jul 28, 2026
other
Martin Madaus Elected to Haemonetics Board of Directors
BOSTON, July 28, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global medical technology company focused on delivering innovative medical
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.29 | $1.21–$1.37 | 1.7% | +0.1% | 6↑ 3↓ | $0.3B | 11 |
| Next Q | $1.36 | $1.25–$1.43 | 3.7% | +0.3% | 3↑ 5↓ | $0.4B | 11 |
| Current FY | $5.31 | $5.25–$5.40 | 7.0% | +0.2% | 11↑ 0↓ | $1.4B | 11 |
| Next FY | $5.78 | $5.47–$6.18 | 8.8% | +0.7% | 3↑ 6↓ | $1.5B | 11 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.291 | — |
| 7d ago | $1.291 | — |
| 30d ago | $1.290 | +0.001 |
| 60d ago | $1.274 | +0.017 |
| 90d ago | $1.276 | +0.015 |
Institutional ownership
Which big funds own HAE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.1B total value (40,950,279 shares) as of 2026-Q2. Top holders: BlackRock,, Neuberger, VANGUARD. Net buying activity: 27 institutions added/increased vs 23 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 5,909,258 | $443.2M | 14.5% | — |
| Neuberger Berman Group LLC | 4,179,443 | $313.5M | 10.2% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,546,394 | $191.0M | 6.2% | — |
| AQR CAPITAL MANAGEMENT LLC | 2,266,489 | $165.0M | 5.4% | — |
| ARIEL INVESTMENTS, LLC | 2,060,966 | $154.6M | 5.0% | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,059,578 | $154.5M | 5.0% | — |
| STATE STREET CORP | 1,818,186 | $136.4M | 4.4% | — |
| DIMENSIONAL FUND ADVISORS LP | 1,585,222 | $118.9M | 3.9% | — |
| CITADEL ADVISORS LLC | 1,510,120 | $113.3M | 3.7% | DOUBLED +485.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,287,240 | $96.6M | 3.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ARIEL INVESTMENTS, LLC | NEW | — | 2,060,966 | — | $154.6M |
| CITADEL ADVISORS LLC | DOUBLED | 258,153 | 1,510,120 | +485.0% | $113.3M |
| UBS Group AG | ADD | 526,617 | 983,378 | +86.7% | $73.8M |
| DEUTSCHE BANK AG\ | ADD | 358,882 | 631,663 | +76.0% | $47.4M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 9,784 | 570,413 | +5730.1% | $42.8M |
| Holocene Advisors, LP | DOUBLED | 4,522 | 550,195 | +12067.1% | $41.3M |
| MORGAN STANLEY | ADD | 293,439 | 466,149 | +58.9% | $35.0M |
| Boston Partners | TRIM | 556,679 | 405,892 | -27.1% | $30.4M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | NEW | — | 332,075 | — | $24.9M |
| CITIGROUP INC | ADD | 251,922 | 320,037 | +27.0% | $24.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 25 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | Pomeroy Claire | Director | AWARD | 2,538 | — | — |
| Jul 24, 2026 | KROLL MARK W | Director | AWARD | 2,538 | — | — |
| Jul 24, 2026 | Johnson Lloyd Emerson | Director | AWARD | 2,538 | — | — |
| Jul 24, 2026 | COYLE MICHAEL J | Director | AWARD | 2,538 | — | — |
| Jul 24, 2026 | Bryant Diane M | Director | AWARD | 2,538 | — | — |
| Jul 24, 2026 | ABERNATHY ROBERT E | Director | AWARD | 2,538 | — | — |
| Jul 24, 2026 | Madaus Martin D | Director | AWARD | 2,538 | — | — |
| Jul 24, 2026 | Zane Ellen M | Director | AWARD | 2,538 | — | — |
| Jun 5, 2026 | Miller Laurie A. | SVP, Human Resources | TAX W/H | 313 | $71.28 | $22.3K |
| Jun 5, 2026 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | TAX W/H | 259 | $71.28 | $18.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for HAE.
Shares short
3,424,696
Settlement Sep 15, 2026
Change vs prior
+19.6%
Semi-monthly cycle
Days to cover
5.7
At avg daily volume
Of shares outstanding
≈7.5%
Estimate — not % of float
All HAE filing & press-release reports (5)
- 8-K reportAug 18, 2026
- DEFA14A reportJun 9, 2026
- 8-K reportJun 5, 2026
- 8-K reportMay 7, 2026
- 8-K reportMay 1, 2026